doxorubicin + cyclophosphamide + docetaxel + trastuzumab

This drug is a combination chemotherapy and targeted therapy regimen used primarily for HER2-positive breast cancer. It consists of four agents: - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA, inhibiting topoisomerase II and generating free radicals, leading to DNA damage and apoptosis in cancer cells. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, preventing cell replication. - **Docetaxel** is a taxane that stabilizes microtubules, inhibiting mitosis and promoting apoptosis. - **Trastuzumab** is a monoclonal antibody targeting the HER2 receptor (Human Epidermal growth factor Receptor 2), blocking its signaling pathways which promote tumor growth. This combination leverages cytotoxic chemotherapy with targeted immunotherapy to improve outcomes in HER2-positive breast cancer patients. The regimen often involves initial cycles of doxorubicin plus cyclophosphamide followed by docetaxel combined with trastuzumab. Clinical trials such as BCIRG 006 have demonstrated improved disease-free survival compared to regimens without trastuzumab[2][3][4]. Cardiac toxicity risk increases with anthracyclines plus trastuzumab but remains manageable under monitoring[2][5].

Brand names

Herceptin (trastuzumab)others depend on individual drugs